

Prevent Protect Promote Prevent Protect Promote Prevent
Prevent Protect Promote Prevent Protect Promote Prevent
Prevent Protect Promote Prevent Protect Promote Prevent

Medicaid's Preferred Drug List (PDL)

for
The Health and Human Services Interim Committee

September 17, 2008



Utah Legislature passed SB 42 in the 2007 General Session

- Allowed the Department of Health to implement a PDL
- Exempted “psychotropic or anti-psychotic drugs”
- Allowed a health care provider to override the PDL with appropriate documentation in the patient file and a handwritten note including the words “medically necessary – dispense as written” on the prescription



Prevent Protect Promote Prevent Protect Promote Prevent
Prevent Protect Promote Prevent Protect Promote Prevent
Prevent Protect Promote Prevent Protect Promote Prevent

What is a PDL?


- A list of drugs organized by drug class given preferential coverage as recommended by a Pharmacy and Therapeutics Committee
- A quality-promotion, cost-containment process for prescription drugs
- A practice that creates savings from secondary rebates and price discounts from market shifts
- It is NOT generic substitution NOR utilization

review



Utah
Department
Health

Medicaid Drug Program Management

Utah
Department
Health

Pharmacy and Therapeutics (P&T) Committee Membership

- Pediatrician
- Internist
- Psychiatrist
- Family Medicine
- Hospital Pharmacist
- Chain Pharmacist
- Community Pharmacist
- Clinical Pharmacist
- Governmental Pharmacist



P&T Committee Process

- Meets monthly
- Evaluates drugs in designated classes for safety and efficacy
- Uses evidence-based criteria from the Oregon Evidence Based Practice Center and the University of Utah College of Pharmacy
- Makes recommendations to UDOH



PDL Savings Summary


State Fiscal Year	Description	General Funds	Total Funds
2008 Actual	Market Shift Savings	\$214,488	\$756,038
	Secondary Rebates	\$397,273	\$1,400,329
	Administrative Expenses	(\$65,876)	(\$213,503)
	PDL Savings	\$545,886	\$1,942,864
2009 Projection	Market Shift Savings	\$564,109	\$1,988,398
	Secondary Rebates	\$664,679	\$2,342,893
	Administrative Expenses	(\$46,790)	(\$137,160)
	PDL Savings	\$1,181,997	\$4,194,131

PDL Market Share Comparison




9


Market Share – Statin



10




Market Share - Oral Hypoglycemic



Utah
Department
of Health


13

Market Share - Diabetic Supply - Lancet




Utah
Department
of Health


14




Market Share - Asthma Inhaled Beta Andrenergic



Market Share - Asthma Inhaled (Combo)




Market Share – Hypotensive (Combo)



Utah
Department
of Health

19

Market Share - Overall



Utah
Department
of Health

20